Latest Ratios: P/E Ratio -27.7x · EV/EBITDA N/A · ROE -42.6%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $6.3B | $3.4B | $1.9B | $766M | $290M | $1.0B | — |
| Enterprise Value | $6.2B | $3.3B | $1.7B | $722M | $-34302410 | $494M | — |
| P/E Ratio → | -27.74 | — | — | — | — | — | — |
| P/S Ratio | 417.77 | 226.28 | — | 111.71 | — | — | — |
| P/B Ratio | 10.43 | 6.44 | 4.78 | 3.24 | 0.86 | 2.06 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 222.70 | — | 105.38 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | — | — | — |
| Operating Margin | -1384.6% | -1384.6% | — | -2499.4% | — | — | — |
| Net Profit Margin | -1316.9% | -1316.9% | — | -2204.7% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -42.6% | -42.6% | -73.9% | -52.8% | -52.2% | -154.4% | -344.2% |
| ROA | -31.2% | -31.2% | -50.3% | -37.6% | -40.3% | -119.1% | -91.0% |
| ROIC | -51.2% | -51.2% | -91.8% | -125.3% | -1291.7% | — | — |
| ROCE | -35.7% | -35.7% | -47.9% | -47.1% | -42.0% | -123.3% | -337.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.29 | 0.36 | 0.21 | 0.15 | 1.82 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.66 | -0.18 | -0.96 | -1.06 | -0.52 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -18.12 | -18.12 | -22.08 | -16.78 | -28.81 | -54.67 | -27.21 |
Net cash position: cash ($61M) exceeds total debt ($8M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 8.57 | 8.57 | 9.25 | 8.00 | 11.42 | 25.52 | 1.30 |
| Quick Ratio | 8.57 | 8.57 | 9.25 | 8.00 | 11.42 | 25.52 | 1.30 |
| Cash Ratio | 6.86 | 6.86 | 8.31 | 6.51 | 10.27 | 24.15 | 0.84 |
| Asset Turnover | — | 0.02 | — | 0.02 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 2085.08 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $136M | $114M | $96M | $93M | $90M | $71M |
Clinical trial funding shortfall
Based on reported figures, Centessa trades at a P/S ratio of 417.77, a valuation multiple that appears disconnected from fundamental performance and reflects market expectations for future clinical success rather than current earnings, as noted in recent financial data and industry-wide biotechnology valuation benchmarks.
The extreme P/S ratio suggests that investors are pricing the company as a pure-play option on its pipeline rather than a going concern with established revenue. This valuation is highly sensitive to binary clinical outcomes, and the lack of forward P/E metrics highlights the absence of a clear path to profitability in the near term.
According to historical financial statements, Centessa’s ROIC has remained consistently negative, reaching -13.2% in 2026Q1, which indicates that the firm is currently destroying invested capital as it funds high-cost clinical trials without generating offsetting returns from commercialized products or licensing milestones.
The persistent negative ROIC trend reflects the structural reality of a clinical-stage biotech where capital is deployed into long-duration R&D projects. Investors should monitor whether the company can achieve a positive inflection point as lead assets like ORX750 approach potential commercialization, though current trends suggest continued capital decay.
As reported in recent filings, the company’s asset turnover ratio remains negligible at 0.03, underscoring the lack of operational efficiency inherent in a pre-revenue business model that relies entirely on external capital to sustain its decentralized research and development activities across multiple subsidiary entities.
The extremely low asset turnover is typical for firms without a commercial product, but it highlights the risk of capital misallocation within the hub-and-spoke structure. Without a significant increase in revenue-generating activities, the efficiency of the company's asset base will likely remain constrained by the high cost of clinical trial execution.
Based on quarterly data, the current ratio has fluctuated significantly, dropping to 9.53 in 2026Q1 from a peak of 21.52 in 2024Q3, which suggests that the company’s liquidity position is rapidly deteriorating as cash reserves are consumed by ongoing Phase III clinical development programs.
While a current ratio above 9.0 appears superficially strong, it masks the reality of a high cash-burn environment where liquid assets are the primary source of survival. The rapid decline in this ratio warrants close monitoring, as it indicates an approaching need for external financing to maintain operational continuity.
As noted in industry research, the P/E ratio is the most commonly misapplied metric for Centessa, as it obscures the company's lack of commercial revenue and ignores the substantial non-cash expenses that distort net income, making it an unreliable indicator of the firm's true intrinsic value.
Investors should instead focus on probability-adjusted net present value (rNPV) of the pipeline, which accounts for clinical success rates and market potential. Relying on P/E or EBITDA-based multiples for a pre-revenue biotech like Centessa leads to misleading conclusions about the company's financial health and long-term viability.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CNTA stock.
Centessa Pharmaceuticals plc's current P/E ratio is -27.7x. This places it at the 50th percentile of its historical range.
Centessa Pharmaceuticals plc's return on equity (ROE) is -42.6%. The historical average is -120.0%.
Based on historical data, Centessa Pharmaceuticals plc is trading at a P/E of -27.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Centessa Pharmaceuticals plc has 100.0% gross margin and -1384.6% operating margin.